Conjugate vaccines cure contagious diseases. It consists of polysaccharide coatings on microorganisms and germs which help to cure the disease. These vaccines link the polysaccharide coatings to a bacterium by producing response& immunity. Some examples of these vaccines are a pneumococcal vaccine, meningococcal vaccine, and Haemophilus influenza type B (Hib) vaccine etc. Meningococcal vaccines are used to prevent meningitis.
The key advantages of conjugate vaccines are longer fixed protection, the formation of herd insusceptibility, better immune & memory response and safety of children& toddlers. Additionally, some of the side-effects are muscle pain, vomiting, low fever, redness, tired feeling, diarrhea, swelling, headache, irritability, obsessiveness, loss of hungriness and sleepiness and many others.
According to study, “North America Conjugate Vaccine Market (2018-2023)” some of the major companies that are currently operating in the North America conjugate vaccine market are Merck & Co. Inc., GlaxoSmithKline, Bavarian Nordic, Sanofi Pasteur SA, Pfizer Inc., SutroVax Inc., CSL Limited, Novartis AG, Nuron Biotech Inc. These key players competing with each other and offer many products with many different brands.
The conjugate vaccine is classified mainly in two type multivalent conjugate vaccines and monovalent conjugate vaccine. Based on the pathogen type, this market is segmented into viral conjugate vaccine market, bacterial conjugate vaccine and combination (bacterial & viral) conjugate vaccine. Based on the disease indication, the market is segmented into meningococcal, pneumococcal, Haemophilus influenza type B (Hib) and diphtheria tetanus pertussis (DTP) etc. In addition, based on the end-user, the market is segmented into adult and pediatric.
The North American conjugate vaccine is largely driven by an increase in diagnosis and treatments. Some of the other growth factors are increasing immunization rates & immunization endorsements, rising in a number of regulatory approvals, growing determinations for the implementation of suitable preventive broadcast methods, improvement in patient compliance, growing commonness of diseases affected by germs (Neisseria meningitides and Streptococcus pneumonia), increasing technological advancements etc.
North America is a soaked market for these vaccines. The growth of the market is registering key challenges of complex production procedure, emerging manufacturers, the situation of oligopoly, uncertainty about the future of government initiatives and low convenience to vaccines in distant areas. In addition, the demand for adult vaccines has reduced due to the decreasing aging population in the region.
The recommended dosages & vaccines are reorganized on a regular basis to fulfill with dominant infectious mediators. The Centers for Disease Control and Prevention (CDC) is a government agency in the U.S, which has its private immunization plan for US inhabitants. It helps in increasing the efficiency of managed vaccines, which thus raises the demand for the manufactured goods, primary to increase in market trades.
It is estimated that the conjugate vaccine market in North America is expected to reach US$ 16.2 billion, at a CAGR of 3.2%, by 2023. In terms of volume, it is expected that the market to reach 286.6 million units, expanding at a CAGR of 3%. It is predicted that the future of the market to be bright due to extensive routine immunization programs in developing economies.
To know more, click on the link below:-
https://www.kenresearch.com/healthcare/pharmaceuticals/north-america-conjugate/172476-91.html
Related Reports:-
https://www.kenresearch.com/healthcare/pharmaceuticals/asia-pacific-conjugate/172469-91.html
https://www.kenresearch.com/healthcare/pharmaceuticals/europe-conjugate-vaccine/172474-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
